← Leaderboards
Binoy Appukuttan
Oregon Health & Science University
$922,784
Attributed
$1,845,567
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $385K · FY2009–13$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$1,845,567 · 1
By mechanism
R01$1,845,567 · 1
Top collaborators
- John T Stout5 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Yali Jia$6,803,157
- Yifan Jian$1,842,606
- John T Stout$3,908,072
- John Peter Campbell$5,273,396
- Thomas Hwang$1,507,875
Others in their field
Top investigators on “Age Related Macular Degeneration”
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Rohit Varma · University Of Southern California$50,124,787
- Maureen G Maguire · University Of Pennsylvania$38,506,792
- Cecilia Sungmin Lee · University Of Washington$32,086,169
- Krzysztof Palczewski · University Of California-Irvine$27,513,979
- Supriya Menezes · The Emmes Company, Llc$25,277,032
Research focus
Age Related Macular DegenerationAnimal ModelAssaultAlternative SplicingBinding (Molecular Function)BlindnessBlood VesselsBolus InfusionBaseCell Culture TechniquesCell NucleusCell ProliferationCellsChimeric ProteinsCofactorComplexDiabetic RetinopathyEffective TherapyEnhancersEnvironmentEnzyme-Linked Immunosorbent AssayEvolutionGene ExpressionGene Expression Regulation
Grant awards (5)
Ocular RTEF-1 Isoforms and Control of VEGF Expression: Implications for Therapy$347,609
R01 · FY2013 · EY
Ocular RTEF-1 Isoforms and Control of VEGF Expression: Implications for Therapy$365,904
R01 · FY2012 · EY
Ocular RTEF-1 Isoforms and Control of VEGF Expression: Implications for Therapy$365,904
R01 · FY2011 · EY
Ocular RTEF-1 Isoforms and Control of VEGF Expression: Implications for Therapy$381,150
R01 · FY2010 · EY
Ocular RTEF-1 Isoforms and Control of VEGF Expression: Implications for Therapy$385,000
R01 · FY2009 · EY